Disease correction in mucopolysaccharidosis type IIIB mice by intraparenchymal or cisternal delivery of a capsid modified AAV8 codon-optimized NAGLU vector
Human Molecular Genetics · 2023
DOI: 10.1093/hmg/ddac209 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Molecular Genetics, 2023. Verfasst von Courtney J Rouse und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Florida College of Medicine, Gainesville, FL, USA. Hauptthemen laut MEDLINE: Mucopolysaccharidosis III. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIDDK NIH HHS, NIDCD NIH HHS.
Abstract (Originalsprache)
Mucopolysaccharidosis type IIIB (MPS IIIB) is an autosomal recessive lysosomal storage disease caused by mutations in the gene that encodes the protein N-acetyl-glucosaminidase (NAGLU). Defective NAGLU activity results in aberrant retention of heparan sulfate within lysosomes leading to progressive central nervous system (CNS) degeneration. Intravenous treatment options are limited by the need to overcome the blood–brain barrier and gain successful entry into the CNS. Additionally, we have demonstrated that AAV8 provides a broader transduction area in the MPS IIIB mouse brain compared with AAV5, 9 or rh10. A triple-capsid mutant (tcm) modification of AAV8 further enhanced GFP reporter expression and distribution. Using the MPS IIIB mouse model, we performed a study using either intracranial six site or intracisterna magna injection of AAVtcm8-codon-optimized (co)-NAGLU using untreated MPS IIIB mice as controls to assess disease correction. Disease correction was evaluated based on enzyme activity, heparan sulfate storage levels, CNS lysosomal signal intensity, coordination, activity level, hearing and survival. Both histologic and enzymatic assessments show that each injection method results in supranormal levels of NAGLU expression in the brain. In this study, we have shown correction of lifespan and auditory deficits, increased CNS NAGLU activity and reduced lysosomal storage levels of heparan sulfate following AAVtcm8-coNAGLU administration and partial correction of NAGLU activity in several peripheral organs in the murine model of MPS IIIB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Florida College of Medicine, Gainesville, FL, USA.
- Lacerta Therapeutics, Alachua, FL, USA.
- Department of Aging and Geriatric Research, University of Florida, Gainesville, FL, USA.
- Department of Chemistry, University of Washington, Seattle, WA, USA.
- Pharmaceutical Chemistry Department, Misr International University, Cairo, Egypt.
ORCID-Profile: Coy D Heldermon
Förderung
- NINDS NIH HHS
- NIDDK NIH HHS
- NIDCD NIH HHS
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke
- National Institute of Neurologic Disorders and Stroke
- National Institute on Diabetes, Digestive and Kidney Disease
- National Institute on Deafness and Communication Disorders
Zitieren
APA
Rouse, C. J., Hawkins, K., Kabbej, N., Dalugdug, J., Kunta, A., Kim, M. J., Someya, S., Herbst, Z., Gelb, M., Dinelli, I., Butterworth, E., Falk, D. J., Rosenkrantz, E., Elmohd, H., Khaledi, H., Mowafy, S., Ashby, F., & Heldermon, C. D. (2023). Disease correction in mucopolysaccharidosis type IIIB mice by intraparenchymal or cisternal delivery of a capsid modified AAV8 codon-optimized NAGLU vector. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddac209
Vancouver
Rouse CJ, Hawkins K, Kabbej N, Dalugdug J, Kunta A, Kim MJ, et al. Disease correction in mucopolysaccharidosis type IIIB mice by intraparenchymal or cisternal delivery of a capsid modified AAV8 codon-optimized NAGLU vector. Human Molecular Genetics. 2023. doi:10.1093/hmg/ddac209
BibTeX
@article{Rouse2023,
author = {Rouse, Courtney J and Hawkins, Kimberley and Kabbej, Nadia and Dalugdug, Justin and Kunta, Aishwarya and Kim, Mi-Jung and Someya, Shinichi and Herbst, Zachary and Gelb, Michael and Dinelli, Isabella and Butterworth, Elizabeth and Falk, Darin J and Rosenkrantz, Erinn and Elmohd, Hamza and Khaledi, Hamid and Mowafy, Samar and Ashby, Frederick and Heldermon, Coy D},
title = {Disease correction in mucopolysaccharidosis type IIIB mice by intraparenchymal or cisternal delivery of a capsid modified AAV8 codon-optimized NAGLU vector},
journal = {Human Molecular Genetics},
year = {2023},
doi = {10.1093/hmg/ddac209}
}
EUVIMED